Lopatniuk M, Ostash B, Luzhetskyy A, Walker S, Fedorenko V
Department of Genetics and Biotechnology, Ivan Franko National University of Lviv, Lviv 79005, Ukraine.
Helmholtz Institute for Pharmaceutical Research, University of Saarland, 66123 Saarbrucken, Germany.
Russ J Genet. 2014 Apr;50(4):360-365. doi: 10.1134/S1022795414040085.
Moenomycins (Mm) are family of phosphoglycolipid natural products that is considered a blueprint to develop new class of antibiotics. The natural Mm producer, (ATCC14672), produces very low amounts of moenomycin, fueling the investigations on genetic approaches to improve its titers. Heterologous expression of moenomycin biosynthesis gene cluster () would be one of the ways to reach this goal. Here we report the generation of a number of novel heterologous streptomycete hosts producing nosokomycin A (one of the members of Mm family), and determine their potential for the antibiotic production. The point mutation in the model strain of genetics, (strain M1152) significantly improved nosokomycin A production compared to parental strains (M145 and M512), while double mutation in the same species (strain M1154) decreased it. Our results point to the previously unanticipated epistatic interactions between mutations that individually are known to be highly beneficial for antibiotic production. We also showed here for the first time that facultative chemolitotrophic streptomycete and chloramphenicol producer can be used as the hosts for genes.
莫能霉素(Mm)是一类磷酸糖脂天然产物,被认为是开发新型抗生素的蓝本。莫能霉素的天然产生菌(ATCC14672)产生的莫能霉素量非常低,这推动了通过基因方法提高其产量的研究。莫能霉素生物合成基因簇()的异源表达将是实现这一目标的方法之一。在此,我们报告了一系列产生诺索霉素A(Mm家族成员之一)的新型异源链霉菌宿主的构建,并确定了它们生产抗生素的潜力。与亲本菌株(M145和M512)相比,遗传模型菌株(菌株M1152)中的点突变显著提高了诺索霉素A的产量,而同一物种中的双突变(菌株M1154)则降低了产量。我们的结果表明,单个已知对抗生素生产非常有益的突变之间存在以前未预料到的上位性相互作用。我们还首次在此表明,兼性化能营养型链霉菌和氯霉素产生菌可作为基因的宿主。